Amgen’s MariTide Shows Promising 20% Weight Loss, Falls Short of Investor Expectations

Weight Loss Results:
Amgen's experimental weight loss injection, MariTide, demonstrated up to 20% weight loss in patients without diabetes and up to 17% in those with diabetes over a 52-week period12.

Investor Reaction:
Despite the significant weight loss, the results fell short of Wall Street's high expectations, leading to disappointment among investors2.

Clinical Trial:
The Phase 2 study evaluated the efficacy of MariTide in treating obesity, with the drug showing promising results but not meeting the lofty expectations set by investors2.

Treatment Duration:
The study spanned 52 weeks, indicating a long-term treatment approach with MariTide12.

Differential Impact:
The drug showed a slightly higher efficacy in patients without diabetes compared to those with diabetes, highlighting potential differences in how the drug works in different patient populations12.

Sources:

1. https://timesofindia.indiatimes.com/life-style/health-fitness/health-news/amgens-experimental-jab-causes-20-per-cent-weight-loss-in-early-results/articleshow/115778705.cms

2. https://www.biopharmadive.com/news/amgen-maritide-obesity-phase-2-data-monthly/733996/